|1.||Tominaga, Takeshi: 6 articles (10/2008 - 03/2002)|
|2.||Shirouzu, Kazuo: 6 articles (11/2007 - 10/2004)|
|3.||Kawate, Susumu: 5 articles (12/2011 - 01/2005)|
|4.||Takeyoshi, Izumi: 5 articles (12/2011 - 01/2005)|
|5.||Sasatomi, Teruo: 5 articles (11/2007 - 01/2005)|
|6.||Ogata, Yutaka: 5 articles (11/2007 - 01/2005)|
|7.||Matono, Keiko: 5 articles (11/2007 - 01/2005)|
|8.||Ishibashi, Nobuya: 5 articles (11/2007 - 01/2005)|
|9.||Oka, Masaaki: 4 articles (08/2013 - 11/2008)|
|10.||Sunose, Yutaka: 4 articles (12/2011 - 01/2005)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/2000 - "Low-dose weekly TXT with oral 5'-DFUR produced a higher response rate, but less hematologic toxicity than full-dose TXT, suggesting that this combination therapy is clinically useful and may be effective for patients with advanced or metastatic breast cancer."
12/15/2006 - "Firstly, we have characterized the nucleoside transporters responsible for 5'-DFUR uptake into the breast cancer cell line MCF7. "
12/15/2006 - "Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells."
01/01/2006 - "Patients with relapsed, advanced breast cancer with evaluable lesions were given 5'-DFUR at 800 mg/day/body and CPA at 100 mg/day/body for 2 weeks, then underwent 2 weeks of drug withdrawal. "
09/01/2003 - "[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients]."
12/01/1981 - "Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index."
01/01/2006 - "After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. "
08/01/2000 - "Prolonged stable disease effects survival in patients with solid gastric tumor: analysis of phase II studies of doxifluridine."
06/15/2015 - "The prodrug metabolism was realized and confirmed within this in vitro liver model as the intermediate product of the prodrug 5'-deoxy-5-fluorouridine (DFUR) was successfully detected with MS after the conditioning of HepG2 cells, and the anti-tumor effect of the active metabolite was observed through cell vitality assays of MCF-7 cells. "
07/01/2013 - "And to discuss the anti-cancer activity of 5'-DFUR to SW480 and LOVO cells. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/2003 - "After administration of 5'-DFUR alone, a decrease of abnormal accumulation on a bone scintigram was obtained in 10 months, the lung metastases were diagnosed as being in complete remission (CR) at 11 months and the lymph node metastases were diagnosed as being in CR at 14 months. "
02/01/2002 - "Three years later she showed multiple bone metastases with elevation of CEA, and 5'-DFUR 1,200 mg/day and MPA 800 mg/day were administered. "
07/01/2000 - "It then became doubtful whether the pulmonary shadows were real metastases or not, and 5'-DFUR administration was discontinued. "
05/01/2000 - "After the treatment regimen was changed to combined chemoendocrine therapy with CPA, EPI, 5'-DFUR, and MPA, the areas of bone metastases were reduced. "
04/01/2005 - "A 42-year-old woman with multiple organ metastases from breast cancer was successfully treated with 5'-deoxy-5-fluorouridine (5'-DFUR) and hormonal therapy (leuprorelin+tamoxifen). "
|4.||Colorectal Neoplasms (Colorectal Cancer)
05/01/2003 - "Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer."
08/01/2010 - "The aim of this study was to search for predictive factors of antitumor effects by analyzing the relationship between clinicopathological factors and the change of PyNPase activity in colorectal tumor tissues after preoperative 5'-DFUR administration. "
01/01/2009 - "However, the results of the present study indicate that 5'-DFUR results in a good prognosis for colorectal cancer patients and is safe over a long / administration period."
08/01/2010 - "The reduction rate of PyNPase activity in colorectal tumor tissues after preoperative 5'-DFUR administration was correlated with significant differences in lymphatic invasion, stage, and histologic classification. "
09/01/2003 - "[Doxifluridine for treatment of colorectal cancer]."
|5.||Stomach Neoplasms (Stomach Cancer)
03/01/2002 - "A previous phase II study of doxifluridine in non-elderly patients with advanced gastric cancer demonstrated a favorable survival with mild toxicity, despite a low response rate. "
03/01/2002 - "A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410)."
01/01/2001 - "[Survival of 2 years and 7 months with 5'-DFUR treatment in a patient with peritoneal gastric cancer recurrence]."
01/01/2001 - "[Effectiveness of high-dose, intermittent 5'-DFUR therapy for advanced gastric cancer]."
09/01/2000 - "Patients aged 75 years or less with advanced gastric cancer were enrolled and randomized into the following groups: Group I, which received oral 5'-DFUR (610 mg/m2/day x 10 days or over) preoperatively, and Group II, which received no treatment preoperatively. "
|10.||Medroxyprogesterone Acetate (Depo-Provera)
|1.||Combination Drug Therapy (Combination Chemotherapy)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)